{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:22:06Z","timestamp":1773069726437,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.radonc.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:55:58Z","timestamp":1520988958000},"page":"62-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer"],"prefix":"10.1016","volume":"127","author":[{"given":"Benedikt","family":"Thomann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Sachpazidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khodor","family":"Koubar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayiotis","family":"Mavroidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Wiehle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimos","family":"Baltas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2018.02.006_b0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.radonc.2015.08.006","article-title":"Residual \u0263H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness","volume":"116","author":"Menegakis","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2007.04.020","article-title":"Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation","volume":"83","author":"Yaromina","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/labinvest.2009.127","article-title":"ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients\u2019 outcome","volume":"90","author":"Li","year":"2010","journal-title":"Lab Investig"},{"key":"10.1016\/j.radonc.2018.02.006_b0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2005.11.044","article-title":"An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance","volume":"65","author":"Carnell","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2016.02.002","article-title":"Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments","volume":"109","author":"Krause","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.radonc.2018.02.006_b0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ctrv.2008.01.006","article-title":"Hypoxia in prostate cancer: a powerful shield against tumour destruction?","volume":"34","author":"Marignol","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2018.02.006_b0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2007.04.019","article-title":"Hypoxia inducible factors, stem cells and cancer","volume":"129","author":"Keith","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.radonc.2018.02.006_b0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","article-title":"Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study","volume":"9","author":"Vergis","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0045","doi-asserted-by":"crossref","unstructured":"Cojoc M, Peitzsch C, Kurth I, et al., Aldehyde dehydrogenase is regulated by -Catenin\/TCF and promotes radioresistance in prostate cancer progenitor cells. Vol. 75. 2015.","DOI":"10.1158\/0008-5472.CAN-14-1924"},{"issue":"27","key":"10.1016\/j.radonc.2018.02.006_b0050","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1016\/j.biomaterials.2014.06.011","article-title":"Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules","volume":"35","author":"Rao","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.radonc.2018.02.006_b0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijrobp.2005.01.019","article-title":"Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro","volume":"62","author":"Arvold","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3892\/etm.2011.373","article-title":"Suppression of HIF-1\u03b1 expression and radiation resistance in acute hypoxic conditions","volume":"3","author":"Oike","year":"2012","journal-title":"Experiment Ther Med"},{"key":"10.1016\/j.radonc.2018.02.006_b0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.7150\/thno.16638","article-title":"Comparison of (68)Ga-HBED-CC PSMA-PET\/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology","volume":"7","author":"Zamboglou","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.radonc.2018.02.006_b0070","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.radonc.2017.04.021","article-title":"Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using (68)Ga-HBED-CC PSMA-PET\/CT: a planning study based on histopathology reference","volume":"123","author":"Zamboglou","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0075","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2007.11.054","article-title":"Observations on real-time prostate gland motion using electromagnetic tracking","volume":"71","author":"Langen","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0080","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ijrobp.2010.08.052","article-title":"Real-time study of prostate intrafraction motion during external beam radiotherapy with daily endorectal balloon","volume":"81","author":"Both","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0085","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0360-3016(02)02882-1","article-title":"Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions","volume":"53","author":"Kitamura","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0090","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00259-015-3257-5","article-title":"MRI versus (68)Ga-PSMA PET\/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer","volume":"43","author":"Zamboglou","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2018.02.006_b0095","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.7150\/thno.15344","article-title":"(68)Ga-HBED-CC-PSMA PET\/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison","volume":"6","author":"Zamboglou","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.radonc.2018.02.006_b0100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: Prostate Cancer","volume":"8","author":"Mohler","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2018.02.006_b0105","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.6004\/jnccn.2012.0114","article-title":"Prostate cancer, version 3.2012: featured updates to the NCCN guidelines","volume":"10","author":"Mohler","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2018.02.006_b0110","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-12-255","article-title":"Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial","volume":"12","author":"Lips","year":"2011","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.radonc.2018.02.006_b0115","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/02841860410002824","article-title":"The radiobiology of prostate cancer including new aspects of fractionated radiotherapy","volume":"44","author":"Fowler","year":"2005","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0125","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.urology.2014.07.060","article-title":"Reduced radiation tolerance of penile structures associated with dose-escalated hypofractionated prostate radiotherapy","volume":"84","author":"McDonald","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2018.02.006_b0130","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1259\/0007-1285-34-400-246","article-title":"The relation between tumour lethal doses and the radiosensitivity of tumour cells","volume":"34","author":"Munro","year":"1961","journal-title":"Brit J Radiol"},{"key":"10.1016\/j.radonc.2018.02.006_b0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/02841868709104364","article-title":"Optimal dose distribution for eradication of heterogeneous tumors","volume":"26","author":"Brahme","year":"1987","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0140","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/028418699432950","article-title":"Optimization of the dose level for a given treatment plan to maximize the complication-free tumor cure","volume":"38","author":"Lind","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0167-8140(97)00162-X","article-title":"The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy","volume":"46","author":"Wheldon","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0150","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/srao.2001.23478","article-title":"Modeling the effects of inhomogeneous dose distributions in normal tissues","volume":"11","author":"Yorke","year":"2001","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0155","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/095530096144743","article-title":"Improved models of tumour cure","volume":"70","author":"Tucker","year":"1996","journal-title":"Int J Radiat Biolol"},{"key":"10.1016\/j.radonc.2018.02.006_b0160","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1088\/0031-9155\/45\/2\/303","article-title":"Tumour control probability: a formulation applicable to any temporal protocol of dose delivery","volume":"45","author":"Zaider","year":"2000","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2018.02.006_b0165","doi-asserted-by":"crossref","first-page":"071707","DOI":"10.1118\/1.4883775","article-title":"Practical aspects and uncertainty analysis of biological effective dose (BED) regarding its three-dimensional calculation in multiphase radiotherapy treatment plans","volume":"41","author":"Kauweloa","year":"2014","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0170","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.radonc.2012.10.006","article-title":"Bioeffect modeling and equieffective dose concepts in radiation oncology - terminology, quantities and units","volume":"105","author":"Bentzen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0180","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1016\/j.ijrobp.2012.01.087","article-title":"Intensity modulated radiation therapy dose painting for localized prostate cancer using (1)(1)C-choline positron emission tomography scans","volume":"83","author":"Chang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.radonc.2016.02.030","article-title":"A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps","volume":"119","author":"Casares-Magaz","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.radonc.2016.02.015","article-title":"Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland","volume":"119","author":"Ghobadi","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0195","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-5347(05)65855-7","article-title":"High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer","volume":"166","author":"Zelefsky","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2018.02.006_b0200","doi-asserted-by":"crossref","unstructured":"Kupelian P, Kuban D, Thames H, Levy E, Horwitz E, and Mart\u00ednez A, Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Vol. 57. 2003. S271-S272.","DOI":"10.1016\/S0360-3016(03)01115-5"},{"key":"10.1016\/j.radonc.2018.02.006_b0205","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3109\/0284186X.2014.925582","article-title":"Survival and tumour control probability in tumours with heterogeneous oxygenation: a comparison between the linear-quadratic and the universal survival curve models for high doses","volume":"53","author":"Lindblom","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0210","doi-asserted-by":"crossref","first-page":"934380","DOI":"10.1155\/2015\/934380","article-title":"Towards multidimensional radiotherapy: key challenges for treatment individualisation","volume":"2015","author":"Toma-Dasu","year":"2015","journal-title":"Comput Math Methods Med"},{"key":"10.1016\/j.radonc.2018.02.006_b0215","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.radonc.2017.08.020","article-title":"Ex vivo gammaH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity","volume":"124","author":"De-Colle","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.02.006_b0220","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijrobp.2007.03.029","article-title":"Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers","volume":"69","author":"Kotte","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0225","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ijrobp.2007.10.049","article-title":"Dosimetric consequences of intrafraction prostate motion","volume":"71","author":"Li","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0230","first-page":"48","article-title":"A method to predict the effect of organ motion and set-up variations on treatment plans","volume":"22","author":"Keall","year":"1999","journal-title":"Australas Phys Eng Sci Med"},{"key":"10.1016\/j.radonc.2018.02.006_b0235","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1088\/0031-9155\/45\/4\/308","article-title":"Evaluation of the validity of a convolution method for incorporating tumour movement and set-up variations into the radiotherapy treatment planning system","volume":"45","author":"McCarter","year":"2000","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2018.02.006_b0240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00066-011-0015-x","article-title":"The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)","volume":"188","author":"Hodapp","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2018.02.006_b0245","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1118\/1.3685586","article-title":"Experimental assessments of intrafractional prostate motion on sequential and simultaneous boost to a dominant intraprostatic lesion","volume":"39","author":"Abdellatif","year":"2012","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0250","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0360-3016(02)02857-2","article-title":"High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients","volume":"53","author":"Zelefsky","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0255","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.006_b0260","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2016.06.046","article-title":"Clinical outcomes for patients with Gleason score 9\u201310 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis","volume":"71","author":"Kishan","year":"2017","journal-title":"Eur Urol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018300628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018300628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T20:15:51Z","timestamp":1570911351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814018300628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0167814018300628"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2018.02.006","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}